TABLE 2.

Specificities of NABs to IFN-α in sera from two patients with severe type II EMC resistant to rIFN-α2aa

IFN-α subtypeNeutralizing activity (t1/10) against subtypes of natural IFN-α
Patient 1Patient 2
124 ± 8<10
2a1,379 ± 291,600 ± 399
5112 ± 64108 ± 3
61,124 ± 11189 ± 8
7a14 ± 533 ± 11
7c83 ± 53136 ± 76
8b<10<10
10a14 ± 349 ± 20
14a<1084 ± 7
17a37 ± 243 ± 4
21a22 ± 13<10
  • a Sera for detection of the neutralizing activity against the different IFN-α preparations were collected before the injection of LeIFN (see text for details). The data are expressed as the means ± standard deviations for three separate experiments.